
The FDA has awarded US approval to Novo Nordisk’s Saxenda (liraglutide) 3mg injection to treat obesity in patients between the …

NICE, the drug watchdog for England and Wales, has revealed that it has chosen not to recommend Novo Nordisk’s Saxenda …

Novo Nordisk has presented analysis covering three years of a late-stage trial for Saxenda (liarglutide 3mg) , which showed the …

Novo Nordisk is rolling out its obesity drug Saxenda across the US for the treatment of obese adult patients. Saxanda …

Novo Nordisk’s obesity drug Saxenda has been approved by the European Commission for use across the EU. This approval follows …

New research by Novo Nordisk has suggested that its obesity drug Saxenda can help improve several other weight-related problems as …

The US Food and Drug Administration has shown Novo Nordisk’s obesity drug Saxenda the green light to aid chronic weight …